Stay Informed on Key Developments

Investor News and Updates

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

281 - 290of 392 News

July 08, 2019

Not intended for U.S. and UK Media - Important step towards improved treatment for children with venous thromboembolism

Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolism

July 02, 2019

LEO Pharma completes the acquisition of Bayer’s prescription dermatology business

July 01, 2019

Century Therapeutics launches with USD 250M financing for induced pluripotent stem cells (iPSC) allogeneic cell therapy platform

June 26, 2019

Bayer Supervisory Board takes action to address the glyphosate litigation and welcomes the appointment of Ken Feinberg as mediator

June 21, 2019

Not intended for U.S. and UK Media

Bayer initiates Phase III trial of Aflibercept to prevent blindness in premature infants

June 19, 2019

Not intended for U.S. and UK Media

Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial

June 03, 2019

Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019:

New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019

May 31, 2019

Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Bayer’s darolutamide plus ADT delays worsening of disease-related symptoms and maintains quality of life beyond end of study treatment compared to placebo plus ADT in men with nmCRPC

May 15, 2019

Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019

New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in primary CNS tumors and brain metastases

May 13, 2019

Bayer statement on jury’s decision in California State Glyphosate Trial

Inform Yourself on Special Topics

Investor News and Updates

Control Weeds, Not Farming

Everything You Need to Know About Glyphosate

Managing Glyphosate Litigation

Managing and Mitigating PCB Litigation Risk